Immuron Ltd — Investor Presentation 2010

Aug 31, 2010

==> picture [193 x 42] intentionally omitted <==

ASX Release

1 September 2010

Immuron Limited ABN 80 063 114 045

IMMURON TO PRESENT SUCCESSFUL RESULTS FROM CLINICAL TRIAL IN PATIENTS WITH NASH AT INTERNATIONAL CONFERENCE

Corporate Details:

ASX Code: IMC

Directors

Chairman:

Prof. Colin Chapman Non-Executive Directors: Prof. Roy Robins-Browne Mr Simon Sallka Dr Elane Zelcer

Chief Executive Officer

Dr Grant Rawlin

Medical Director Prof. Yaron Ilan

Substantial Shareholder Hadasit Medical Research 17.96%

Immuron (ASX: IMC) reports that two posters detailing its recent work on the treatment of the liver disease non-alcoholic steatohepatitis (NASH) and aspects of metabolic syndrome have been accepted for presentation at the Liver Meeting in Boston (Oct 29 – Nov 2). This conference is the 61[st] Annual Meeting of the American Association for the Study of Liver Diseases.

The meeting will be attended by over 7500 delegates who include key opinion leaders, clinicians, executives and other representatives of pharmaceutical companies active in this field. The two posters will cover Immuron’s recent successful phase I/II clinical trial involving its hyperimmune bovine colostrum products for the treatment of NASH and aspects of metabolic syndrome (announced 23 August 2010) and earlier animal studies. In addition, poster abstracts have been accepted for publication in the October 2010 edition of the Hepatology journal.

The poster presentations are expected to provide a forum for further discussion of the results with potential commercial partners, a number of which have already expressed particular interest in this project.

NASH is a chronic inflammatory disorder of the liver, also known as fatty liver disease. It is associated with type II diabetes, excessive amounts of fats inside liver cells (hepatic steatosis) and abnormal liver function. It is a more aggressive form of non-alcoholic fatty liver disease (NAFLD).

Contact Details:

Immuron Limited Level 1 39 Leveson Street North Melbourne VIC 3051 Australia

NASH is more prevalent in the obese population and is an independent risk factor for the development of metabolic syndrome and cardiovascular complications. The increase of obesity worldwide is likely to raise the incidence of both NAFLD and NASH, with the associated outcomes of liver failure and cardiovascular disease. The United States National Center for Infectious Diseases has predicted that about 25 million Americans will be affected by NASH in 2025. At present about 5% of Americans are affected, with a similar incidence in Australia.

Health authorities across the globe are already overburdened with the results of metabolic syndrome such as obesity, liver disease, type II diabetes, and hyperlipidemia (excess lipids such as cholesterol in the blood stream).

Tel: +61 (0)3 9018 4880 www.immuron.com

Currently, there is no approved and effective treatment for the chronic liver disease NASH, which could ameliorate the disease in patients and the associated economic burden. The treatment of NASH is a significant area of unmet need. With the incidence rising, treatment of NASH represents a large and growing market currently estimated to be worth multiple billions of dollars.

Immuron’s Chief Executive Officer, Dr Grant Rawlin, said: “Our recent clinical trial demonstrated that we have two product candidates for the treatment of NASH, one of the most common liver diseases in the western world. We are delighted to have the opportunity to share our findings at one of the most prestigious liver disease conferences in the world.”

ENDS

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy using dairy-derived polyclonal antibody products for humans. Current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as type II diabetes and fatty liver (NASH), and prevention of influenza. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and the University of Melbourne (Australia).

About NASH and Metabolic Syndrome

NASH (non-alcoholic steatohepatitis) is one of the most common liver diseases in the western world. It is associated with obesity, diabetes and hyperlipidaemia. It affects 5% of the lean population, 20% of the obese population and 50% of morbidly obese people. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver (hence another of its names ‘Non-alcoholic Fatty Liver Disease) along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to function properly. The potential NASH market is estimated to be a multi-billion dollar market.

Metabolic Syndrome is a combination of medical disorders (type II diabetes, fatty liver disease, atherosclerosis, hyperlipidaemia) that increases the risk of cardiovascular disease and diabetes. It affects one in five people, and its prevalence increases with age. Some studies estimate the prevalence in the USA and Australia to be up to 25% of the population. The causes of metabolic syndrome are complex and not fully understood. A common trait is insulin resistance where the body does not use the hormone insulin as effectively as it should, especially in the muscles and liver. When a person has insulin resistance, the pancreas needs to release more insulin than usual to maintain normal blood glucose levels.

For more information please contact:

Dr Grant Rawlin – Chief Executive Officer Immuron Ltd Tel: +61 3 9018 4880 Email: grant@immuron.com

Prof Colin Chapman – Chairman Immuron Ltd Tel: +61 3 9018 4880

Media Relations:

Fay Weston – Director Talk Biotech Pty Ltd Tel: +61 2 4885 2662 or +61 (0)422 206036 Email: fayweston@talkbiotech.com.au